TikTok Accused of Testing Fake Safety Tools on Users 
Rapidus Seeks Chip Customers as Japan Pushes 2nm Semiconductor Revival 
HSBC Plans Deep UK Wealth Job Cuts in AI Push 
San Francisco Halts New Data Center Construction With 45-Day Moratorium 
Levi Strauss Beats Q3 Profit Estimates, Raises 2026 Outlook 
GSR Commits $100M to Hare Onchain Credit Vaults 
Robinhood Buys $25 Million in Bitcoin for Corporate Treasury 
Europol Warns Bitcoin Wallets Face Quantum Computing Risk 
Evernorth XRPN Nasdaq Listing Delayed to October 12 
Anthropic Expands Claude Access for Cyber Defense Teams 
Zcash Privacy Demand Rises as AI Exposes Bitcoin Transactions 
SpaceX Seeks $40 Billion for Nvidia AI Chips 
Broadcom, Oracle and SpaceX Seek Billions in Private Debt for AI Expansion 
Constellation Brands Beats Q2 Estimates, Buys SpikedAde 
Bitmine to Stop Ethereum Buying After Reaching 5% ETH Supply 
Gate Launches Gate Money as Crypto Super App Race Heats Up 
Add as a preferred source on Google
SK Biopharmaceutical is eyeing a share of the 4 trillion won US antiepileptic drug market with its cenobamate tablet Xcopri, which treats partial-onset seizures in adults.
The drug, approved by the US Food and Drug Administration (FDA) on November 21 last year, provides an extra needed treatment option for people with seizures.
Xcopri is the first Korean novel drug, researched and developed entirely and independently by a Korean pharma firm, notes SK Biopharmaceutical CEO Cho.
It is a product of Cho's 15-year research and development drive.
According to the US FDA, the safety and efficacy of XCOPRI were established in two studies that enrolled 655 adults, which were randomized, double-blind, and placebo-controlled.
The FDA granted Xcopri's approval to SK Life Science Inc., the US arm of SK Biopharmaceutical.
Thus, SK Life Science will undertake the US distribution of Xcopri.
